Kymera Investor Presentation Deck

● Phase 1 results in healthy volunteers and patients support Phase 2 advancement Sanofi responsible for program development costs Kymera retains option (before Phase 3) for cost and profit sharing First development milestone achieved in Q4 2023 $40 million for first patient dosed in HS trial Additional milestone payable upon first patient dosed in AD trial Topline data from two ongoing trials expected 1H 2025 Kymera and Sanofi evaluating opportunities to expand indications beyond HS and AD ● KT-474: Oral Agent with Potential to Achieve Broad, Well-Tolerated Anti-Inflammatory Effect in Multiple Diseases ● KYMERA ©2023 KYMERA THERAPEUTICS, INC. PAGE 19

View entire presentation